In a challenging year for Aclarion, the medical technology company's stock has plummeted to a 52-week low, trading at $4.41. According to InvestingPro data, the company maintains a healthy liquidity ...
BROOMFIELD, Colo. - Aclarion, Inc. (NASDAQ:ACON, ACONW), a healthcare technology company, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent ...
Aclarion (ACON) has received a Notice of Allowance from the United States Patent and Trademark Office for its 24th issued US patent. Whereas ...
Recent Notice of Allowance is for Aclarion’s 24th issued US patent Propionic acid (PA) is a biomarker the literature suggests may be indicative of bacterial infection and pain in an ...
Aclarion's new patent extends MRS use for identifying propionic acid as a biomarker for infections and pain beyond intervertebral discs. Aclarion, Inc. has announced the receipt of a Notice of ...
Insider Monkey on MSN9d
Aclarion, Inc. (ACON) Showcases AI-Powered NOCISCAN for Chronic Back Pain Diagnosis at Selby Spine ConferenceWe recently compiled a list of the 12 AI News and Ratings You Should Not Miss. In this article, we are going to take a look ...
Aclarion stock is trading higher on Tuesday after the company announced it secured funding for its CLARITY trial of its ...
Aclarion, Inc. has announced that Northwestern Medicine will serve as the initial site for its pivotal clinical trial, CLARITY, designed to assess the effectiveness and economic value of Nociscan ...
Aclarion, Inc. (NASDAQ: ACON) shares cleared breakeven Tuesday, as the health-care technology company announced it has received a Notice of Allowance from the United States Patent and Trademark Office ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback